4.1 Article

Study design and implementation of the PRecision Medicine In MEntal health Care (PRIME Care) Trial

期刊

CONTEMPORARY CLINICAL TRIALS
卷 101, 期 -, 页码 -

出版社

ELSEVIER SCIENCE INC
DOI: 10.1016/j.cct.2020.106247

关键词

Major depressive disorder; Pharmacogenetic testing; Implementation; Clinical trial; Veterans

资金

  1. United States (U.S.) Department of Veterans Affairs, Health Services Research and Development Service [1P1 HX002375-01/SDR 16-348]
  2. Mental Illness Research, Education, and Clinical Center at the Corporal Michael J. Crescenz VA Medical Center (CMCVAMC)

向作者/读者索取更多资源

Genomic testing has the potential to improve patient outcomes by personalizing medication selection, but there are challenges in implementing it in routine clinical care, which requires considering clinical utility, informatics support, and patient and provider education.
Genomic testing has the potential to improve patient outcomes and reduce patient care costs by personalizing medication selection. Commercial pharmacogenetic (PGx) testing for psychotropic and other medications is widely available and promoted as a means to implement precision medicine. Despite evidence that genetic variation affects the metabolism of psychotropic medications, the clinical utility of these test results has not been established. Moreover, implementing such testing in routine clinical care is complex, requiring informatics support and a systematic approach to patient and provider education. The PRIME Care program is designed to bridge this gap, applying both clinical trials and implementation science methods to conduct a program of research. It is centered on a large, pragmatic randomized clinical trial (RCT) in which 2000 Veterans with a major depressive disorder (MDD) and their health care providers are randomized together to receive PGx test results at the beginning of an episode of care or 6 months later. We hypothesize that providers who receive the PGx test results will prescribe an antidepressant guided by the PGx findings and Veterans whose care is guided by PGx testing will experience higher rates of remission from MDD. If the results of the trial replicate those of prior PGx studies, which provided preliminary evidence of the utility of PGx guided prescribing, it would strongly support using a precision medicine approach to treat MDD. This program of research is also evaluating dissemination influencers, other biomarkers (e.g., genetic variation associated with depression response), and the health care cost implications of PGx testing. ClinicalTrials.gov Identifier: NCT03170362.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.1
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据